The Development of Gene Editing Technology and Controversial Issues: A Discussion

Yirui Wu

doi:10.54097/6gj0tk11

Authors

Yirui Wu

DOI:

https://doi.org/10.54097/6gj0tk11

Keywords:

CRISPR/Cas; effects; ethics, laws.

Abstract

The fields of genetics and biomedicine stand to benefit greatly from the innovative technique known as gene editing technology, especially with the potential uses of CRISPR-Cas9.the creation of crops resistant to disease, the treatment of genetic illnesses, and the advancement of biomedical research in fields like sickle-cell anemia and rice gene editing are all made possible by CRISPR-Cas9's capacity to precisely pinpoint and edit specific genes. Despite being beneficial to humanity, the quick development of human gene editing technology has also brought up ethical, legal, societal, and technical issues. Its management, informed consent, privacy, and social equality are among the issues that require considerable attention.In an effort to give the scientific community something to think about, this article examines the state of gene editing today, its potential for the future, and the debates surrounding its application. It concentrates on the way the CRISPR/Cas system works, how CRISPER/Cas9 gene editing is used, and the range of problems it has brought up.

Downloads

Download data is not yet available.

References

Gao Weisong,Dou Jinping,Wei Shuang et al.Classification and research status of CRISPR/Cas system[J]. Advances in Biotechnology,2022,12(04): 532-538.DOI:10.19586/j.2095-2341.2021.0198

ZHAO Guohua, PU Jiali, TANG Beisha.ZFN, TALEN and CRISPR/Cas9 gene editing technologies in disease research and gene therapy[J]. Chinese Journal of Medical Genetics, 2016, 33(6):6. DOI: 10.3760/cma.j.issn.1003-9406.2016.06.025.

Humbert O, Radtke S, Samuelson C, Carrillo RR, Perez AM, Reddy SS, Lux C, Pattabhi S, Schefter LE, Negre O, Lee CM, Bao G, Adair JE, Peterson CW, Rawlings DJ, Scharenberg AM, Kiem HP. Therapeutically relevant engraftment of a CRISPR-Cas9-edited HSC-enriched population with HbF reactivation in nonhuman primates. Sci Transl Med. 2019 Jul 31;11(503): eaaw3768. doi: 10.1126/scitranslmed. aaw3768. PMID: 31366580; PMCID: PMC8407476.

Kan J, Cai Y, Cheng C, Chen S, Jiang C, He Z, Yang P. CRISPR/Cas9-guided knockout of eIF4E improves Wheat yellow mosaic virus resistance without yield penalty. Plant Biotechnol J. 2023 May;21(5):893-895. doi: 10.1111/pbi.14002. Epub 2023 Jan 24. PMID: 36628413; PMCID: PMC10106853.

Tao J, Bauer DE, Chiarle R. Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing. Nat Commun. 2023 Jan 13;14(1):212. doi: 10.1038/s41467-023-35886-6. PMID: 36639728; PMCID: PMC9838544.

Sinha S, Barbosa K, Cheng K, Leiserson MDM, Jain P, Deshpande A, Wilson DM 3rd, Ryan BM, Luo J, Ronai ZA, Lee JS, Deshpande AJ, Ruppin E. A systematic genome-wide mapping of oncogenic mutation selection during CRISPR-Cas9 genome editing. Nat Commun. 2021 Nov 11;12(1):6512. doi: 10.1038/s41467-021-26788-6. Erratum in: Nat Commun. 2022 May 16;13(1):2828. PMID: 34764240; PMCID: PMC8586238.

Ihry RJ, Worringer KA, Salick MR, Frias E, Ho D, Theriault K, Kommineni S, Chen J, Sondey M, Ye C, Randhawa R, Kulkarni T, Yang Z, McAllister G, Russ C, Reece-Hoyes J, Forrester W, Hoffman GR, Dolmetsch R, Kaykas A. p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. Nat Med. 2018 Jul;24(7):939-946. doi: 10.1038/s41591-018-0050-6. Epub 2018 Jun 11. PMID: 29892062.

Baylis F, McLeod M. First-in-human Phase 1 CRISPR Gene Editing Cancer Trials: Are We Ready? Curr Gene Ther. 2017;17(4):309-319. doi: 10.2174/1566523217666171121165935. PMID: 29173170; PMCID: PMC5769084.

He Yiyi. Ethical Reflections on Human Gene Editing Technology [D]. Henan Normal University, 2023.DOI: 10.27118/d.cnki.ghesu.2021.000295.

XU Xiangyun, YUE Zongxu, CHENG Siyan. Re-examination of the social risk of gene editing technology--The case of "designer babies"[J]. Journal of Changsha University of Technology (Social Science Edition),2023,38(01): 66-74.DOI: 10.16573/j.cnki.1672-934x.2023.01.008.

Jiang Li. Research on international legal governance of human gene editing[J]. Life Science,2023,35(10): 1388-1397.DOI: 10.13376/j.cbls/2023151

Cadigan RJ, Waltz M, Henderson GE, Conley JM, Davis AM, Major R, Juengst ET. Scientists' Views on Scientific Self-Governance for Human Genome Editing Research. Hum Gene Ther. 2022 Nov;33(21-22):1157-1163.